Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6R-BH4 in Sickle Cell Disease
NCT00445978Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- May 2007
- Primary completion
- Aug 2008
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapropterin in sickle cell disease (SCD), sponsored by BioMarin Pharmaceutical. Primary endpoint: Treatment Emergent Adverse Events at 16 weeks. Started May 2007; status: completed.
02
Drugs
sapropterin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00445978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445978.